Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma-Reference-Cited by-同舟云学术

Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma

Published:2005 Issue:8 Volume:103 Page:1644-1651
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Hornberger John C.,Best Jennie H.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference37 articles.

1. American Cancer Society. Cancer facts and figures. Atlanta: American Cancer Society, Inc., 2002.

2. Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients

3. Management of Cancer in the Older Person: A Practical Approach

4. Phase II Study of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated, Aggressive Non-Hodgkin’s Lymphoma

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of Rituximab-abbs versus Rituximab in Patients with Diffuse Large B-Cell Lymphoma in a Noninferiority Study;BioDrugs;2024-06-27

2. Prognosis and complete remission rate of diffuse large B‐cell lymphoma patients in standard R‐CHOP with reduction of vincristine: A retrospective study;Health Science Reports;2023-11-28

3. Sensitivity Analysis in Economic Evaluations of Immuno-Oncology Drugs: A Systematic Literature Review;Value in Health Regional Issues;2023-09

4. Cost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin’s lymphoma;The European Journal of Health Economics;2023-04-14

5. Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma;Blood;2022-12-22